Physiological Associations and Prognostic Discrimination of an EIT-Derived Flow Index During Noninvasive Ventilation (NIV-EFI)
Physiological Associations and Prognostic Discrimination of an Electrical Impedance Tomography-Derived Flow Index During Noninvasive Ventilation: A Multicenter Prospective Cohort With a Nested Physiological Substudy
This is a multicenter prospective observational cohort study with a nested physiological substudy. It aims to enroll 220 adults with acute hypoxemic respiratory failure (AHRF) initiating mask noninvasive ventilation (NIV). The study will assess the measurement feasibility, physiological associations, and early prognostic discrimination of the electrical impedance tomography (EIT)-derived flow index (EFI) during NIV. The primary objective is to estimate how well pre-landmark T1 EFI discriminates the risk of endotracheal intubation or all-cause death through 48 hours. A nested physiological substudy (n=20) will evaluate the within-patient association between EFI and airway occlusion pressure across fixed pressure support (PS) levels (5, 10, and 15 cmH2O). Clinical management remains independent of study measurements.
研究概览
地位
详细说明
This study will enroll adults with AHRF for whom the treating team has decided to initiate mask NIV. The main cohort (n=220) is observational. EIT data will be acquired at baseline (T0), 60-120 min (T1), 20-24 h (T2), and 42-48 h (T3). The primary predictor is the median EFI across valid breaths during T1 (before the 2-h landmark). The primary endpoint is the first occurrence of endotracheal intubation or all-cause death after 2 h and through 48 h among patients eligible at the 2-h landmark.
A nested, non-randomized physiological substudy (n=20) will be conducted after T1. After confirming safety and obtaining separate informed consent, patients will undergo a fixed sequence of brief pressure support steps (PS 5, 10, and 15 cmH2O) with EPAP and FiO2 held at clinical settings. Brief airway occlusions will be performed at each level to measure occlusion pressure (Pocc and P0.1). The substudy aims to estimate the within-patient association between EFI and |Pocc|. The study was approved by the Ethics Committee of Ruijin Hospital (Approval No. 2026846). Written informed consent is obtained from all participants (and separate consent for the substudy).
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Rui Zhang
- 电话号码:+86-18801119381
- 邮箱:ccmzhangrui@foxmail.com
学习地点
-
-
Shanghai Municipality
-
Shanghai、Shanghai Municipality、中国、200025
- Department of Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
-
接触:
- Yun Feng
- 电话号码:+86-17321113771
- 邮箱:fy11697@rjh.com.cn
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Adults (aged 18 years or older) with acute hypoxemic respiratory failure (AHRF) for whom the treating clinical team has decided to initiate mask noninvasive ventilation (NIV) in the intensive care unit. A subset of stable patients will participate in the nested physiological sub-study.
描述
Inclusion Criteria:
- Age 18 years or older.
- Clinical diagnosis of AHRF and a decision to initiate NIV through an oronasal or full-face mask (PaO2/FiO2 ≤ 300 mmHg or FiO2 ≥ 0.40 to maintain oxygenation target).
- Consent and enrollment completed before NIV begins or within 60 min of initiation.
- Written informed consent from the patient or authorized representative (separate consent for substudy).
Exclusion Criteria:
- Immediate clinical need for endotracheal intubation or clear contraindication to NIV.
- Facial trauma, severe chest-wall skin injury, or incisions preventing safe placement of EIT belt.
- Contraindication in EIT device manual (e.g., incompatible implanted device).
- Pregnancy or lactation.
- Baseline do-not-intubate (DNI) decision or comfort measures only.
- Inability to obtain valid consent.
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
Main Cohort
Adults with AHRF initiating mask NIV (n=220). Observational; T1 EFI is evaluated for discriminating 48-hour intubation or death. |
Standard clinical care through oronasal or full-face mask. Settings are directed by the treating team. Continuous EIT monitoring to derive the dimensionless flow index (EFI). |
|
Nested Physiological Substudy
A subset of the main cohort (n=20). Consenting patients undergo brief, sequential pressure support (PS) adjustments (5, 10, 15 cmH2O) and airway occlusions to measure EFI and |Pocc| associations. |
Standard clinical care through oronasal or full-face mask. Settings are directed by the treating team. Continuous EIT monitoring to derive the dimensionless flow index (EFI). Protocol-specified PS steps (5, 10, 15 cmH2O) and device-supported airway occlusions performed in the physiological substudy. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of Endotracheal Intubation or All-Cause Death (2h to 48h)
大体时间:After 2 hours through 48 hours.
|
The first occurrence of endotracheal intubation or all-cause death after 2 hours and through 48 hours from NIV initiation, among patients alive and still receiving NIV at the 2-hour landmark.Unit of Measure: Proportion of participants (or Event count) |
After 2 hours through 48 hours.
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Discrimination Performance (AUC) of T1 EFI
大体时间:Within 72 hours
|
Area under the receiver operating characteristic curve (AUC) of the pre-landmark T1 EFI for predicting the primary composite endpoint.Unit of Measure: AUC (dimensionless, 0-1) |
Within 72 hours
|
|
Within-Patient Association between EFI and |Pocc|
大体时间:Within 2 to 6 hours after NIV initiation.
|
The within-patient slope of the association between EFI and the absolute magnitude of occlusion pressure (|Pocc|) across fixed pressure support levels in the physiological sub-study. Unit of Measure: cmH2O per unit of EFI |
Within 2 to 6 hours after NIV initiation.
|
|
Intubation or Death by Day 7
大体时间:Within day 7
|
ncidence of endotracheal intubation or all-cause mortality by day 7.Unit of Measure: Proportion of participants |
Within day 7
|
|
28-Day All-Cause Mortality
大体时间:within day 28
|
All-cause mortality rate at day 28.Unit of Measure: Proportion of participants |
within day 28
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他研究编号
- 2026846
- (2026) Lin Lun Shen No. 846 (其他标识符:Ethics Committee of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
De-identified analysis datasets may be shared on reasonable request for verification, subject to ethics approval.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.